Novel oral anticoagulants: Pharmacology, coagulation measures, and considerations for reversal


Journal Article

Novel oral anticoagulants (NOAC) provide an effective and, in some cases, superior alternative to traditional, oral vitamin K antagonists such as warfarin. These drugs differ in their pharmacokinetic and pharmacodynamics profiles, which is important for selecting the right drug for the right patient. A concern among clinicians is a virtual absence of guidance from clinical trials for reversing the anticoagulant effects of these drugs in clinical settings such as life-threatening bleeding or a need for emergent procedures that carry bleeding risk. In this review, we discuss NOAC, the role of coagulation assays to assess their systemic anticoagulants effects, and the available data supporting strategies designed to reverse or attenuate these effects. © 2013 Springer Science+Business Media.

Full Text

Duke Authors

Cited Authors

  • Jackson, LR; Becker, RC

Published Date

  • January 1, 2014

Published In

Volume / Issue

  • 37 / 3

Start / End Page

  • 380 - 391

Electronic International Standard Serial Number (EISSN)

  • 1573-742X

International Standard Serial Number (ISSN)

  • 0929-5305

Digital Object Identifier (DOI)

  • 10.1007/s11239-013-0958-0

Citation Source

  • Scopus